Jun 17, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
Amylin Pharmaceuticals To Present New Data And Insights From The Company's Diabetes P
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2203313" data-attributes="member: 124445"><p>Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON™ (exenatide extended-release for injectable suspension) at the American Diabetes Association's (ADA's) 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29. The Company will also webcast an investor presentation on Sunday, June 27 at 7:30 PM ET... <a href="http://feedads.g.doubleclick.net/~a/ZkaruY0UidyT8KTZSxBQdnZgM-U/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/ZkaruY0UidyT8KTZSxBQdnZgM-U/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/ZkaruY0UidyT8KTZSxBQdnZgM-U/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/ZkaruY0UidyT8KTZSxBQdnZgM-U/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/Gdk8Nf8drSA" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/Gdk8Nf8drSA/3F6w" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2203313, member: 124445"] Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON™ (exenatide extended-release for injectable suspension) at the American Diabetes Association's (ADA's) 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29. The Company will also webcast an investor presentation on Sunday, June 27 at 7:30 PM ET... [URL="http://feedads.g.doubleclick.net/~a/ZkaruY0UidyT8KTZSxBQdnZgM-U/0/da"][IMG]http://feedads.g.doubleclick.net/~a/ZkaruY0UidyT8KTZSxBQdnZgM-U/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/ZkaruY0UidyT8KTZSxBQdnZgM-U/1/da"][IMG]http://feedads.g.doubleclick.net/~a/ZkaruY0UidyT8KTZSxBQdnZgM-U/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/Gdk8Nf8drSA[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/Gdk8Nf8drSA/3F6w]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top